Postoperative Adjuvant Chemoradiotherapy ± PD-1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma.

ABSTRACT:

Background

Postsurgical immunotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) remains elusive. This study assesses the value and significance of postoperative immunotherapy in the treatment of locally advanced HNSCC.

Methods

In total, 212 patients with locally advanced HNSCC who underwent radical surgery were stratified into three treatment groups: adjuvant radiotherapy alone, adjuvant chemoradiotherapy (CRT), and adjuvant chemoradiotherapy plus immunotherapy (PD-1 Ab). A comprehensive analysis was conducted to assess survival outcomes and prognostic factors across diverse patient cohorts.

Results

Four patients were lost to follow-up, with a follow-up rate of 98.1% and a median follow-up time of 41 months (IQR 24-68). A total o

SUBMITTER: Wang Z 

PROVIDER: S-EPMC12947766 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature